君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

休市中 01-09 16:08:35

25.160

+1.200

+5.01%

最高25.380	最低23.680	成交量384.20万
今开24.200	昨收23.960	日振幅7.10%
总市值258.39亿	流通市值65.42亿	总股本10.27亿
成交额9,481万	换手率1.48%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":25.16,"timestamp":1767946115005,"preClose":23.96,"halted":0,"volume":3842004,"delay":0,"floatShares":260000000,"shares":1027000000,"eps":-1.4525650319995635,"marketStatus":"休市中","change":1.2,"latestTime":"01-09 16:08:35","open":24.2,"high":25.38,"low":23.68,"amount":94813471,"amplitude":0.070952,"askPrice":25.16,"askSize":1200,"bidPrice":25.14,"bidSize":17600,"shortable":3,"etf":0,"ttmEps":-1.071499121504798,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":7,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":23.96,"openAndCloseTimeList":[[1767922200000,1767931200000],[1767934800000,1767945600000]],"volumeRatio":1.3754453546440282,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":39.2,"timestamp":1767942000000,"preClose":37.66,"halted":0,"volume":13556700,"delay":0,"premium":"-42.56"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2602533190","title":"每周股票复盘：君实生物（688180）董事长增持A股10万股耗资383.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533190","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533190?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:53","pubTimestamp":1768067589,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，君实生物报收于39.2元，较上周的34.16元上涨14.75%。截至2026年1月10日，熊俊通过集中竞价方式累计增持A股100,000股，约占总股本0.01%，累计成交金额383.84万元。本次增持计划尚未实施完毕，熊俊将继续择机增持。君实生物H股公告显示，截至2025年12月31日，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股总数为260,295,700股，在香港联交所上市；A股总数为766,394,171股，在上海证券交易所科创板上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1515","BK1161","BK0239","399300","BK1583","688180","159982"],"gpt_icon":0},{"id":"2602585844","title":"小核酸药物行业跟踪点评：技术迭代驱动 慢病市场打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2602585844","media":"光大证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602585844?lang=zh_cn&edition=full","pubTime":"2026-01-10 00:00","pubTimestamp":1767974400,"startTime":"0","endTime":"0","summary":"这意味着小核酸药物的战场已从肝脏疾病全面扩展至代谢、肺部、肌肉萎缩等肝脏外领域。从“跟随”到“并跑”，中国小核酸药物行业BD 出海创历史新高：中国小核酸药物行业在2025 年迎来了质的飞跃。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110112653a4b29978&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110112653a4b29978&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","01801","01877","BK1583"],"gpt_icon":0},{"id":"2602585841","title":"每日卖空追踪 | 君实生物 01月09日卖空量成交1.76万股，卖空比例为0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602585841","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602585841?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:30","pubTimestamp":1767947425,"startTime":"0","endTime":"0","summary":"君实生物北京时间01月09日，涨5.01%，卖空量成交1.76万股，较上一交易日减少81.03%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163633a4af81f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163633a4af81f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1515","01877","BK1161"],"gpt_icon":0},{"id":"2602884312","title":"【券商聚焦】华泰证券：开年以来的流动性修复有望提振创新药板块β","url":"https://stock-news.laohu8.com/highlight/detail?id=2602884312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602884312?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:58","pubTimestamp":1767920334,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，自9月港股创新药年内新高以来，港股创新药指数截止到年底回调24%，而同期美股生物科技指数XBI涨幅29%，NBI指数涨幅18%。XBI自4月底部反弹超过100%，大型MNC普遍自底部反弹30~50%，礼来市值首次突破万亿美金。步入新的一年，港股创新药迎来开门红。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，该机构认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0315179316.USD","159992","IE0008369823.USD","02269","06978","BK1500","LU0043850808.USD","02142","601688","09995","BK1141","LU1960683339.HKD","01877","LU0516423174.USD","01177","06160","LU0516422952.EUR","LU1152091168.USD","09926","LU2097828474.EUR","LU1934453819.USD","LU2097828805.USD","LU1226287792.SGD","IE00B5MMRT66.SGD","LU1807302812.USD","LU0307460666.USD","LU0516422440.USD","01093","LU1064131003.USD","BK1589","01801","LU1328277881.USD","02616","BK0012","LU0067412154.USD","LU0502904849.HKD","06185","LU0501845795.SGD","BK0183","LU0417516571.SGD","LU2148510915.USD","09688","LU2476274720.SGD","LU1993786604.SGD","LU1242518857.USD","LU3063872942.SGD","LU0039217434.USD","LU0588546209.SGD","LU1979443071.USD"],"gpt_icon":0},{"id":"2601776758","title":"君实生物：公司董事长熊俊先生的增持计划尚未实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2601776758","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601776758?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:38","pubTimestamp":1767785928,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日，君实生物在互动平台回答投资者提问时表示，截至本回复日，公司董事长熊俊先生的增持计划尚未实施完毕，熊俊先生将在增持计划实施期间内择机增持公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611635637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1161","01877","BK1515","688180","BK0239"],"gpt_icon":0},{"id":"2601382239","title":"每日卖空追踪 | 君实生物 01月06日卖空量成交1.24万股，卖空比例为0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601382239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601382239?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:30","pubTimestamp":1767688225,"startTime":"0","endTime":"0","summary":"君实生物北京时间01月06日，涨1.49%，卖空量成交1.24万股，较上一交易日减少75.97%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163412a6f983cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163412a6f983cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2601852542","title":"上海君实生物医药科技股份有限公司发布2025年12月证券变动月报，总股本及已发行股份数维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2601852542","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601852542?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:16","pubTimestamp":1767665776,"startTime":"0","endTime":"0","summary":"中访网数据 上海君实生物医药科技股份有限公司于2026年1月5日向香港交易及结算所有限公司提交了截至2025年12月31日的证券变动月报表。报告显示，公司在报告期内股本结构保持稳定，未发生已发行股份及库存股份的变动。具体而言，H股已发行股份为260,295,700股，A股已发行股份为766,394,171股。　　综上所述，上海君实生物在2025年12月未进行新股发行、股份回购或库存股份转让，总股本及股权激励计划下的潜在股份发行数量均保持不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260106/31918345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688180","BK1574","BK0239","BK1583","01877","09939","161027","BK1515","159938","BK1161"],"gpt_icon":0},{"id":"1107759154","title":"上海君实生物（01877/688180）12月无新增发行，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1107759154","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107759154?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:39","pubTimestamp":1767602395,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司于2026年1月5日披露2025年12月股份变动月报表。公告显示，截至2025年12月31日，公司注册股本为人民币1,026,689,871元，分为普通股H股及普通股A股两类，分别于香港联合交易所有限公司和上海证券交易所科创板上市。报告期内，公司未发生新增发行、购回或注销股份等事宜，整体股本维持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"gpt_icon":1},{"id":"2601005950","title":"每日卖空追踪 | 君实生物 01月05日卖空量成交4.4万股，卖空比例为1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601005950","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601005950?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601824,"startTime":"0","endTime":"0","summary":"君实生物北京时间01月05日，涨2.69%，卖空量成交4.4万股，较上一交易日增加57.14%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163526a49e293f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163526a49e293f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1515","BK1583","BK1161"],"gpt_icon":0},{"id":"2601000322","title":"君实生物01月05日主力净流入1043.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000322?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:16","pubTimestamp":1767600964,"startTime":"0","endTime":"0","summary":"01月05日, 君实生物股价涨2.69%，报收22.88元，成交金额9419.6万元，换手率1.60%，振幅8.53%，量比1.47。君实生物今日主力资金净流入1043.7万元，上一交易日主力净流出92.1万元。该股近5个交易日上涨1.51%，主力资金累计净流入275.6万元；近20日主力资金累计净流入870.3万元，其中净流入天数为8日。该股主力净额占比0.18%，港股市场排名52/2709。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105162344a49e1b00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105162344a49e1b00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2601000594","title":"迈威生物：阿达木单抗注射液在印度尼西亚获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000594","media":"生物药大时代","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000594?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:39","pubTimestamp":1767584379,"startTime":"0","endTime":"0","summary":"近日，创新型生物制药公司迈威生物宣布其阿达木单抗注射液 9MW0113，已获得印度尼西亚食品药品监督管理局的注册批准。这是迈威生物2025年收获的第三个海外上市批件。9MW0113 由迈威生物和君实生物合作开发，是印尼 BPOM 批准的首个由中国自主研发的阿达木单抗生物类似药。迈威生物董事、高级副总裁、董秘胡会国表示：\"印尼是东南亚人口最多的国家，医药需求日益增长。此次获批是迈威生物阿达木单抗在东南亚市场获得的重要认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105131309a6f468ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105131309a6f468ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2601021958","title":"中国创新药大爆发，一年出海狂揽9400亿，超越美国","url":"https://stock-news.laohu8.com/highlight/detail?id=2601021958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601021958?lang=zh_cn&edition=full","pubTime":"2026-01-04 20:41","pubTimestamp":1767530460,"startTime":"0","endTime":"0","summary":"热潮从已披露的数据可见，2025年，中国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，远超2024年全年519亿美元和94笔。中国创新药交易额已占全球总额的49%，一举超过美国。其中，新一代IO基石疗法IBI363与武田制药达成共同开发协议，双方将在全球共同开发，并在美国共同商业化。有别于中国创新药出海的传统路径，在这种创新的“合伙人模式”下，中国药企不再是单纯的授权方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104204611a49af4fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104204611a49af4fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01877","BK1583","06978","BK1515"],"gpt_icon":0},{"id":"2600042608","title":"JAMA Oncol：特瑞普利单抗 vs达卡巴嗪？中国晚期肢端型黑色素瘤一线治疗的疗效与安全性评估","url":"https://stock-news.laohu8.com/highlight/detail?id=2600042608","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600042608?lang=zh_cn&edition=full","pubTime":"2026-01-04 13:25","pubTimestamp":1767504300,"startTime":"0","endTime":"0","summary":"JAMA Oncology发表了一项在中国11个中心进行的多中心、开放标签的III期随机临床试验（MELATORCH研究），旨在比较PD-1抑制剂特瑞普利单抗与达卡巴嗪在晚期肢端型黑色素瘤一线治疗中的疗效与安全性。肢端黑色素瘤在中国占所有病例的50%，且预后较差，而西方国家主要以非肢端皮肤黑色素瘤为主。尽管免疫治疗已改变晚期黑色素瘤的治疗格局，但针对未经治疗的肢端黑色素瘤患者，PD-1抑制剂的疗效与安全性缺乏高质量证据支持。在中国，对于无BRAF突变的晚期黑色素瘤，化疗（尤其是达卡巴嗪）一直是唯一的一线标准治疗方案，但其疗效有限。MELATORCH研究为这一临床难题提供了关键答案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104133317a499b6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104133317a499b6fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1515","01877"],"gpt_icon":0},{"id":"2600958063","title":"每日卖空追踪 | 君实生物 01月02日卖空量成交1.52万股，卖空比例为1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600958063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600958063?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:30","pubTimestamp":1767342626,"startTime":"0","endTime":"0","summary":"君实生物北京时间01月02日，涨4.4%，卖空量成交1.52万股，较上一交易日减少66.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163305a6eb2a11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163305a6eb2a11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1161","BK1515"],"gpt_icon":0},{"id":"2600035453","title":"每周股票复盘：君实生物（688180）募投项目延期至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035453?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:59","pubTimestamp":1767290347,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，君实生物报收于34.99元，较上周的35.41元下跌1.19%。国泰海通证券股份有限公司关于上海君实生物医药科技股份有限公司募集资金投资项目延期的核查意见君实生物因项目实际进展需要，拟将2022年度向特定对象发行A股股票的募投项目实施期限进行调整。创新药研发项目实施期限由2025年12月延期至2028年12月，上海君实生物科技总部及研发基地项目由2025年12月延期至2026年6月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","01877","BK1515","BK0239","BK1161","BK1583"],"gpt_icon":0},{"id":"2594222040","title":"君实生物获准注册200亿元科技创新票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2594222040","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594222040?lang=zh_cn&edition=full","pubTime":"2025-12-28 19:32","pubTimestamp":1766921576,"startTime":"0","endTime":"0","summary":"金吾财讯| 上海君实生物医药科技股份有限公司于2025年12月28日自愿发布公告称，公司近日收到中国银行间市场交易商协会下发的《接受注册通知书》。根据通知书，交易商协会接受公司科技创新票据注册，注册额度为人民币200亿元，注册额度自通知书落款之日起2年内有效，由上海银行股份有限公司主承销。公司可在注册有效期内分期发行科技创新票据，发行前需依据相关规定履行备案程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228195141a6d907fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228195141a6d907fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1583","01877","BK1161"],"gpt_icon":0},{"id":"2594222025","title":"君实生物新增一起对外投资，被投资公司为宁波甬元兴仑君金创业投资合伙企业（有限合伙）","url":"https://stock-news.laohu8.com/highlight/detail?id=2594222025","media":"证券之星APP","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594222025?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:55","pubTimestamp":1766865309,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP显示，君实生物新增一起对外投资事件，被投资公司为宁波甬元兴仑君金创业投资合伙企业，法定代表人，投资占比为49%。目前，君实生物共存在对外投资39项，投资占比前20的项目见下表：通过天眼查大数据分析，上海君实生物医药科技股份有限公司共对外投资了42家企业，参与招投标项目43次；财产线索方面有商标信息170条，专利信息119条，著作权信息10条；此外企业还拥有行政许可141个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228040210a6d6e916&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228040210a6d6e916&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"2594244012","title":"每周股票复盘：君实生物（688180）获准注册20亿元中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2594244012","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594244012?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:26","pubTimestamp":1766863572,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，君实生物报收于34.99元，较上周的35.41元下跌1.19%。本周，君实生物12月23日盘中最高价报35.49元。本周关注点公司公告汇总：君实生物收到交易商协会通知，科技创新债券注册获受理，注册金额为20亿元。注册品种为中期票据，注册金额为20亿元，注册额度自通知书落款之日起2年内有效，由上海银行股份有限公司主承销。公司将根据授权及监管要求择机实施发行，并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1583","688180","01877","BK0239","BK1161"],"gpt_icon":0},{"id":"2594524829","title":"京东健康与君实生物达成战略合作 独家首发新一代口腔黏膜敷料“速舒®”","url":"https://stock-news.laohu8.com/highlight/detail?id=2594524829","media":"宿迁网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594524829?lang=zh_cn&edition=full","pubTime":"2025-12-27 15:59","pubTimestamp":1766822374,"startTime":"0","endTime":"0","summary":"近日，京东健康与本土创新生物制药企业君实生物正式达成战略合作，共同推动肿瘤患者口腔黏膜炎护理的生态化服务升级。12月27日，新一代口腔黏膜液体敷料（速舒）在京东健康独家首发，为患者提供精准、规范、便捷的全链路口腔健康解决方案。京东健康始终致力于提升医疗健康服务的精准性与可及性。此次携手君实生物首发速舒口腔黏膜液体敷料，也标志着京东健康在肿瘤护理细分领域的服务能力进一步深化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227171724a6d59433&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227171724a6d59433&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06618","BK1571","BK1589","LU0456827905.SGD","SGXZ86797644.SGD","BK1615","BK1161","BK1142","01877","BK1515","BK1583","BK1247","LU0051755006.USD","SGXZ62798434.SGD","86618","BK1591"],"gpt_icon":0},{"id":"2594212506","title":"临港集团加速培育生物医药：以“基金+基地”模式撬动1700亿元基金规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2594212506","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594212506?lang=zh_cn&edition=full","pubTime":"2025-12-27 11:15","pubTimestamp":1766805354,"startTime":"0","endTime":"0","summary":"目前，该集团正以“一流园区创新生态集成服务商和总运营商”的定位，加速培育生物医药等前沿产业。龚伟表示，立足“十五五”规划关键节点，集团正从“空间提供者”转型“生态构建者”，针对生物医药产业特性，以“基金+基地”模式撬动1700亿元基金规模，构建“接力式”资金加速体系。据介绍，“招投联动”是临港生物医药产业生态赋能的关键引擎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227111804a6d4be4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227111804a6d4be4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1515","01877"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":0.1293},{"period":"1month","weight":0.0706},{"period":"3month","weight":-0.1494},{"period":"6month","weight":0.0798},{"period":"1year","weight":1.347},{"period":"ytd","weight":0.179}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.076039},{"month":2,"riseRate":0.857143,"avgChangeRate":0.07747},{"month":3,"riseRate":0.714286,"avgChangeRate":0.049127},{"month":4,"riseRate":0.857143,"avgChangeRate":0.101581},{"month":5,"riseRate":0.428571,"avgChangeRate":0.004505},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}